Pyrexar Medical In The News

Interior New Pyrexar Medical Headquarter

SALT LAKE CITY – Pyrexar Medical, world leaders in thermal therapy / hyperthermia cancer treatment systems announces the company’s move to a new corporate headquarters. After five months operating in the former BSD Medical building, Pyrexar Medical has moved into its new corporate office and manufacturing facility. The new facility increases the headquarters footprint by fifty percent. The move allows for a revamped manufacturing and QC process, with additional space for research and development.

Part of the rebuilding of the hyperthermia brand includes shedding off outdated manual manufacturing processes and transferring information management to the cloud. Acquisition the of latest in ERP/MRP, CRM and CAD software, increases data stability, and brings company wide transparency from lead acquisition, thru the sales process, to delivery and service.  These investments not only increase productivity but also are aimed at keeping an eye on the bottom line.

“Creating a new workflow has been an enjoyable project for the team.” Says Mark Falkowski. “We have already reduced manufacturing time by two thirds and expect to see a significant cost reduction and immediate return on investment.”

The new building, located minutes from Salt Lake International airport, creates gateway access to the company’s worldwide distribution network; with offices in China, Japan, Taiwan, Germany, UK, South Korea, Spain, UAE, Iran, and Turkey.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

Thermal Therapy reaches South Korea’s Cancer Patients

Seoul, Korea – Pyrexar Medical, leaders in thermal therapy systems for cancer treatment, announced the delivery of two new BSD-2000 Deep Regional Hyperthermia systems to prominent hospitals in South Korea.  Pyrexar’s  Field Service Manager, Ray Lauritzen, was joined by local distributor HanBeam Technology, for the onsite installation and training.  Recipients of the first BSD-2000 systems in Korea are the newly opened Healer’s Care Hospital in the city of Busan and the YCH Cancer Hospital in Seoul. Both oncology groups were looking forward to treating patients with the new systems.

South Korea has the eighth highest cancer rate in the world, just below the United States. Tracking cancer statistics in the country is the KCCR (Korea Central Cancer Registry), a nationwide hospital-based cancer registry established by the Ministry of Health and Welfare. According to the KCCR, stomach and colorectal cancer are some of the highest incidence of cancer among men and women in the country.

Hyperthermia, also known as thermal therapy, is clinically proven to boost the effectiveness of radiation therapy and chemotherapy in cancer patients. Thermal therapy works by increasing blood flow and oxygenation to the tumor site.  As an adjunct therapy to radiation treatment, hyperthermia increases the number of oxygen radicals that can be produced to destroy cancer cells.  When used with chemotherapy, thermal therapy treatments sensitize the tumor site allowing more cancer killing agents to target the tumor.

“We are certain this technology is the beginning of improved clinical outcomes in the region and we will continue to expand our market reach by working with channel partners throughout the world.” said Mark Falkowski, CEO. “Pyrexar continues to deliver the best advanced technological in the thermal therapy marketplace.”

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.  For information about purchasing our products in South Korea, contact HanBeamTek.com

Pyrexar receives final authorization to sell Thermal Therapy devices in Korea

Pyrexar’s line of hyperthermia-based cancer treatment products has received approval from the Korea Good Manufacturing Practice (KGMP).  Similar to ISO 13485 quality system standards, KGMP is required by the Korea Ministry of Food and Drug Safety (MFDS) and opens the door for shipment to, and use of, Pyrexar products in South Korea.

The MFDS, formerly known as the KFDA (Korea Food and Drug Administration), is a South Korea government agency responsible for promoting the public health by ensuring the safety and efficiency of foods, pharmaceuticals, medical devices and cosmetics as well as supporting the development of the food and pharmaceutical industries. In addition to their goal to offer people safe foods and drugs that perform as prescribed.

“We are looking forward to participating in the South Korea medical device marketplace,” says Mark Falkowski, CEO Pyrexar Medical.  “Korea ranks 11th in GDP and per capita healthcare expenditures are rising. We believe our products can be put to good work in this country”.

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.
 
To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.  For information about purchasing our products in South Korea, contact HanBeamTek.com

ORB Healthcare signs contract with Pyrexar Medical

PYREXAR HT Hyperthermia products find distribution with ORB Corporation

SALT LAKE CITY, UT,  --  Pyrexar Medical, the makers of PYREXAR HT Hyperthermia-based cancer treatment systems, announced today it is expanding into Central Asia under the help and guidance of ORB Healthcare, a division of ORB Global Ltd.

Hyperthermia is a type of cancer treatment in which tumors are exposed to elevated body temperatures between 40°C and 45°C. Research has shown that these high ‘fever temperatures’ can damage and kill cancer cells with little to no impact on normal tissues. Since hyperthermia increases blood flow, the result is increased oxygen levels in tumor cells, making them more sensitive to radiation. Hyperthermia has been a vital tool in the fight against cancer and higher clinical response is achieved when hyperthermia is combined with radiotherapy and chemotherapy.

ORB has been selected as the exclusive distribution partner of the PYREXAR HT line of hyperthermia products in several markets across Europe and Asia, including Turkey, Kazakhstan and Azerbaijan. “We are very pleased to have ORB Global as a distribution partner. This five million dollar agreement demonstrates their commitment to fighting cancer around the world.” says Mark Falkowski, CEO of Pyrexar Medical. “ORB is a rapidly rising star in the healthcare industry and we look forward to their expertise in these new markets”.

“We have experience in the hyperthermia marketplace and were looking for a more progressive partner who would help take this beneficial therapy to new heights”, says Mr. Golsharifi, CEO of ORB Global, “We chose Pyrexar based on the company’s highly experienced senior executive team, their commitment to product innovation, and their commitment to support the growing hyperthermia community”. ORB plans to work closely with government officials, hospitals, private clinics and a range of oncologists and physicians in order to expand the positive impact of hyperthermia. In addition to Central Asia, they will also represent Pyrexar in the United Kingdom, Japan and Western Asia.

ABOUT ORB:
ORB Corporation exists to help meet the energy, healthcare & pharmaceutical, food & agricultural, and IT & networking needs of a rapidly changing world. ORB strives to find, extract, trade, refine, store and transport materials and resources from where supply is abundant to where demand is great. With offices located in the UK, Turkey, Iran, UAE, Japan, Canada, Hong Kong and China, they will continue to forge new connections, make things happen, and help markets work. www.orbhealthcare.com

ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues. For more information please visit our web page at: www.pyrexar.com

PYREXAR HT Hyperthermia products find a distribution with Orientech

SALT LAKE CITY, UT - Pyrexar Medical, was invited to China to speak about the use of hyperthermia in the treatment of cancer. Scientists, researchers, and clinicians met at the Dailan #2 Hospital in the city of Dailan in the Liaoning Province of China to exchange information.

According to the GLOBALCAN study, cancer is the second leading cause of death in the Chinese population and the leading cause of death in urban areas. Lung cancer is the most common cancer, followed by stomach, liver, esophageal, and colorectal cancers.

Hosted by Oreintech, speakers from around the region provided clinical data and usage cases supporting the use of thermal therapies in the treatment of cancer.  Representing the United States was Pyrexar Chief Technical Officer Paul Turner. The event also included Dr. Yingying Huang and Dr. Li Ding from Beijing Hospital Oncology Department and Qing Zhang from Beijing Chinese Medicine Hospital (affiliated to The Capital University of Medical Sciences). Topics presented at the conference included:  Deep Hyperthermia with Phased Array Methods and Clinical Application; Hyperthermia Combined with Taxol in Malignant Ascites Treatment; Hyperthermia Combined with Chemotherapy in Gastrointestinal Tumors Treatment; and Green Therapy in Oncology-Application of BSD-2000 Annular Phased Array Methods

During the visit, Pyrexar negotiated a new multi-unit purchase agreement for the BSD-2000 Deep Regional Hyperthermia system with Orientech. "Pyrexar is pleased to have Orientech as a distribution partner in China,” says Mark Falkowski, CEO Pyrexar Medical. “Their long commitment to hyperthermia technologies makes them the ideal choice.” In addition, Orientech is also exploring applications where superficial hyperthermia systems, like the BSD-500, may be beneficial to the people of China.

ABOUT ORIENTECH:
Orientech is a leading manufacturer and distributor of hyperthermia systems in China. With more than 20 years of experience in hyperthermia and oncology, Orientech has developed a highly effective and efficient sales, support, and service network throughout China.  In addition to the Oncology Division, Orientech has four other divisions that specialize in Medical Imaging, Orthopedics and Trauma, Wound Management, and Medical Aesthetics, respectively.
Orientech is based in Dalian, China. For more information, please visit www.orientech.net.

ABOUT PYREXAR MEDICAL:
With the acquisition of BSD Medical assets, Pyrexar Medical takes its place as the pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe, and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing the toxicity of healthy tissues.

Multi-center clinical trials in the US, Europe, and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high-risk soft tissue sarcoma, melanoma, and other malignancies.


Pyrexar Medical is based in Salt Lake City, UT, USA. For more information, please visit our web page at www.pyrexar.com

Hyperthermia products find distribution in South Korea

Salt Lake City, UT - (April 14, 2015) - Pyrexar Medical, the makers of PYREXAR HT Hyperthermia-based cancer treatment systems, announced today that it had received orders for the first two units, of a multi-unit contract, for the BSD-2000 Deep Regional Hyperthermia Systems from the distribution group HanBeam Technology.

Hyperthermia is a type of cancer treatment in which tumors are exposed to elevated body temperatures, between 104˚ and 113°F. Research has shown that high temperatures can damage and kill cancer cells, usually with minimal injury to healthy tissues. Hyperthermia treatment has achieved a high clinical response when combined with radiotherapy in the treatment of cancer. “We are very pleased to have HanBeam Technology as a distribution partner,” says Mark Falkowski, CEO. “HanBeam has a solid reputation as a radiation solutions provider in the Korean peninsula.”

ABOUT HANBEAM TECHNOLOGY:
HanBeam Technology Co., Ltd is known for installing the world’s first single-room proton therapy system and the world’s first View Ray system combining MRI, radiation cancer treatment, Intraoperative Radiation Therapy (IORT) and the BSD-2000 Hyperthermia system capable of thermal cancer treatment. The company is supplying and managing cutting-edge cancer treatment equipment to South Korea and beyond. Building on medical equipment expertise and experiences, the company has spearheaded the adoption of advanced medical equipment to the country.

For the past decade, the company contributed to the use of enhanced robotic radiosurgery by providing Cyberknife to major Korean cancer treatment centers and university hospitals, improving patient care in the hospital environment

Multi-center clinical trials in the US, Europe, and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high-risk soft tissue sarcoma, melanoma, and other malignancies.
Pyrexar Medical is based in Salt Lake City, UT, USA. For more information, please visit our web page at www.pyrexar.com

Pyrexar Medical Media Contact:
Drew Wilkens
VP of Digital Marketing
844-797-3927
This email address is being protected from spambots. You need JavaScript enabled to view it.

Promising Cancer Treatment Technology Now Under New Leadership

Salt Lake City, UT– (April 2, 2015) – Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon (NASDAQ:PRSN), formerly BSD Medical (NASDAQ:BSDM). This acquisition includes substantially all hyperthermia assets, products, services, and related intellectual property.

Medical device industry veteran Mark Falkowski has been named Chief Executive Officer, bringing to Pyrexar more than 30 years of successful executive leadership experience with prominent medical companies like GE Healthcare, Imatron, Carestream, and OEC/Diasonics.

Mr. Falkowski recruited seasoned capital equipment executives, A. Robert Depalma, Brian Chard, Rex Harmon, and Drew Wilkens. Also joining former Perseon employees Paul Turner, Ray Lauritzen, Richard Faux, Dennis Bradley, and a group of highly trained system design, production, and customer support team members directly associated with the hyperthermia product line. The new group’s goal is to build a sales and customer-focused company.

Mr. Falkowski said: “New minimally invasive treatment technologies are vital to winning the fight against cancer, and I look forward to taking an active part in bringing this important cancer-fighting medical technology to market.”

Pyrexar will be presenting and exhibiting at the upcoming Society for Thermal Medicine Annual Meeting in Orlando, FL (April 14-17, 2015).

ABOUT PYREXAR MEDICAL:
With the acquisition of BSD Medical assets, Pyrexar Medical takes its place as the pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe, and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing the toxicity of healthy tissues.

Multi-center clinical trials in the US, Europe, and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high-risk soft tissue sarcoma, melanoma, and other malignancies.

Pyrexar Medical is based in Salt Lake City. For more information, please visit our web page at www.pyrexar.com

Pyrexar Medical Media Contact:
Drew Wilkens
VP of Digital Marketing
844-797-3927
This email address is being protected from spambots. You need JavaScript enabled to view it.

###